New Triple-Threat cancer therapy enters first human safety tests

This early-stage trial is testing the safety and best dose of a three-drug combination (vemurafenib, cetuximab, and irinotecan) for patients with advanced solid tumors that have spread and carry a specific BRAF gene mutation. The goal is to see if combining these drugs—two that block cancer cell growth and one that helps the immune system attack the tumor—is a safe and potentially more effective treatment. The study will enroll about 33 patients to determine the safest dose and look for early signs that the treatment might work.